Clinical Trials Logo

Filter by:
NCT ID: NCT06314594 Recruiting - Clinical trials for Adolescent Scoliosis

the Individualized Stepwise Treatment Mode of Adolescent Idiopathic Scoliosis

Start date: December 20, 2023
Phase: N/A
Study type: Interventional

Based on the risk factors affecting adolescent scoliosis found in the previous social survey, this project adopts the paradigm based on transfer learning and semi-supervised learning, and uses mathematical methods such as multiple learning methods and Transformer image classification algorithms to develop and verify the early warning model and stepped treatment model of adolescent scoliosis, and conducts cost-effect analysis.

NCT ID: NCT06314542 Recruiting - Lung Cancer Clinical Trials

Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data

Start date: January 1, 2013
Phase:
Study type: Observational

Eligibility criteria for cancer drug trials are generally too stringent, leading to key issues such as low enrolment rates and lack of population diversity. In order to evaluate the REC of NSCLC drug trials, this study will use deep learning methods to construct a structured real-world database of NSCLC across dimensions, and quantitatively assess the independent contribution of changes in each eligibility criterion to patient numbers, clinical efficacy and safety.

NCT ID: NCT06314529 Recruiting - Thalassemia, Beta Clinical Trials

Long-term Follow-up Study of BHC001 for TDT

Start date: December 14, 2022
Phase:
Study type: Observational

Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.

NCT ID: NCT06314373 Recruiting - Clinical trials for Advanced Solid Tumors

A Study for HSK39775 in Participants With Solid Tumors

Start date: March 7, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

NCT ID: NCT06314334 Recruiting - Clinical trials for Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

Start date: March 4, 2023
Phase: Phase 2
Study type: Interventional

Extranodal NK/T-cell lymphoma, nasal type (NKTCL) is a common malignant tumor in East Asian populations, often starting in the nasal cavity and spreading to other organs. Associated with EBV infection, NKTCL is aggressive. Early-stage patients typically receive chemo and radiotherapy, with promising outcomes. Recent studies show the potential of immune checkpoint inhibitors in NKTCL treatment. However, optimal treatment sequencing and efficacy remain unclear. This study aims to compare three strategies: (A) Pegaspargase with Sintilimab and radiotherapy; (B) chemo then radiotherapy (PGemOx); (C) sandwich chemoradiotherapy (GELAD). The goal is to identify the best treatment based on 24-month progression-free survival.

NCT ID: NCT06314152 Recruiting - Chronic Pain Clinical Trials

3-point With 1-point Mesh Fixation in TAPP for Inguinal Hernia

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This study was designed to compare the outcome of 3 point with 1 point lightweight mesh fixation in TAPP surgery for patients with inguinal hernia. The main outcome include seroma, chronic pain, recurrence, et al.

NCT ID: NCT06313983 Recruiting - Breast Cancer Clinical Trials

A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Start date: January 8, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of Hemay022 combined with AI (exemestane or letrozole) in the treatment of ER+/HER2+ advanced breast cancer patients based on the progression-free survival (PFS) assessed by the independent review committee (IRC). The second purpose of this study is to evaluate the pharmacokinetics and efficacy of Hemay022 in combination with AI, and the safety of Hemay022 in combination with AI. The trial plans to recruit 339 subjects, who will be randomly divided into two cohorts (the experimental group is hemay022 combined with AI, and the control group is lapatinib combined with capecitabine). During the treatment period, imaging examinations and anti-tumor efficacy evaluations will be performed regularly until the subject develop disease progression or starts receiving other treatments or dies or refuses to come to the hospital for follow-up or the trial is terminated, etc.

NCT ID: NCT06313957 Recruiting - Clinical trials for Refractory B-cell Non-Hodgkin Lymphoma

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.

NCT ID: NCT06313866 Recruiting - Stroke Clinical Trials

the Clinical Effect of TCM Sniffing Therapy Combined With Electroacupuncture in PSCI

Start date: December 20, 2023
Phase: N/A
Study type: Interventional

The patients with cognitive impairment after stroke were divided into control group, electroacupuncture group, olfactory therapy group, and electroacupuncture combined with olfactory therapy group, with 35 people in each group. After the end of the treatment, the clinical efficacy was evaluated.

NCT ID: NCT06313567 Recruiting - Gastric Cancer Clinical Trials

Metronomic Capecitabine in Stage III Gastric Cancer

Start date: March 10, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.